Docusign Envelope ID: CC26837E-7440-4B61-934D-6A924C413AD1

# **CV Sciences** Certificate of Analysis



# This document is to certify that units of the lot number below were tested and found to comply with CV Sciences finished product specifications.

PRODUCT NAME:	SAMPLE ID:	
Strength:	Expiration Date:	
Lot Number:	Total Quantity Produced:	
PHYSICAL PROPERTIES STATUS	S (PASS/FAIL)	METHOD
Appearance		
Color		
Aroma		
CANNABINOIDS*	IG/UNIT	METHOD
CBD		
CBDA		
d9-THC		
THCA-A		
d8-THC		
THCV		
CBDV		
CBDVA		
CBGA		
CBG		
CBN		
СВС		
CBL		
Total Cannabinoids		
Unit Weight		
THC by Mass		
OTHER ACTIVE INGREDIENTS**	IG/UNIT	METHOD
Palmitoylethanolamide (PEA)		
	S (PASS/FAIL)	METHOD
Arsenic		
Cadmium		
Mercury		
Lead		
CV SCIENCES   9530 PADGETT STREET, SUITE 107   SAN DIEGO, CA 921	26 CVSCIENCES.COM	

Docusign Envelope ID: CC26837E-7440-4B61-934D-6A924C413AD1

# **CV Sciences** Certificate of Analysis



м	ICROBIOLOGY*	STATUS (PASS/FAIL)	METHOD
М	lold/Mildew/Yeast		
Ae	erobic Bacteria		
Co	oliforms		
E.	Coli		
Sa	almonella		
Ps	seudomonas		

PESTICIDES***	STATUS (PASS/FAIL)	METHOD
Total Pesticides		
Mycotoxins	Pass	
RESIDUAL SOLVENTS***	STATUS (PASS/FAIL)	METHOD
Total Residual Solvents		

- 1. The hemp extract is the product of a batch tested by the independent testing laboratory;
- 2. The batch contained a total delta-9-tetrahydrocannabinol concentration that did not exceed 0.3 percent pursuant to the testing of random sample of the batch; and
- 3. The batch does not contain contaminants unsafe for human consumption.<sup>+</sup>

<sup>†</sup>Tested analytes and limits were set by CV Sciences, Inc.

#### DB Labs Sample ID #:

\*Actual analytical results obtained by DB Labs (Las Vegas, NV), CV Sciences' third-party testing laboratory.

#### Advanced Botanical Consulting & Testing Sample ID #:

\*\*Actual analytical results obtained by Advanced Botanical Consulting & Testing, Inc. (Tustin, CA), CV Sciences' third-party testing laboratory.

#### Anresco Laboratories Sample ID #:

\*\*\*Actual analytical results obtained by Anresco Laboratories (San Francisco, CA), CV Sciences' third-party testing laboratory.

This Certificate of Analysis has been generated to document product test results. The "Prepared By" signature does not indicate finished product release for distribution.

QUALITY APPROVAL			
Prepared By / Date	Approved By / Date	Status	In
Vandana Kothari	Signed by Vandana Kothari		07
	Vandana tethan I approve the document 01-021-2024 (08-48 POT 87-01 10FF032487368008EED0888E356		



#### September 21, 2024

### CV SCIENCES, INC.

9530 Padgett Street, Suite 107 San Diego, CA 92126 Order No. 560989 Sample No. 1244239

**Certificate of Analysis** 

#### SAMPLE INFORMATION

Description	FP-24-0086 PlusCBD Relief Softgels 60ct SKU 608 exp 07/26
Lot Number	A107220824
Category (Type)	Non-Inhalable Edible (Capsule)
Received	September 17, 2024

#### ANALYTICAL RESULTS

Analysis	Cannabinoid Profile (Non-Plant) 🛛 🔮 Pass
Instrument	Liquid Chromatography Diode Array Detector (LC-DAD)
Method	MF-CHEM-15
Analysis Date	September 17, 2024 to September 21, 2024

Cannabinoid	mg/g	%	mg/serving	mg/package	Status
∆8-THC	ND	ND	ND	ND	-
Δ9-THC	ND	ND	ND	ND	Pass
Δ9-THCA	ND	ND	ND	ND	-
THCV	ND	ND	ND	ND	-
THCVA	ND	ND	ND	ND	-
CBD	25.66	2.566	21.50	644.99	-
CBDA	16.65	1.665	13.95	418.50	-
СВС	ND	ND	ND	ND	-
CBCA	ND	ND	ND	ND	-
CBDV	<loq< td=""><td><loq< td=""><td><loq< td=""><td><loq< td=""><td>-</td></loq<></td></loq<></td></loq<></td></loq<>	<loq< td=""><td><loq< td=""><td><loq< td=""><td>-</td></loq<></td></loq<></td></loq<>	<loq< td=""><td><loq< td=""><td>-</td></loq<></td></loq<>	<loq< td=""><td>-</td></loq<>	-
CBG	ND	ND	ND	ND	-
CBGA	<loq< td=""><td><loq< td=""><td><loq< td=""><td><loq< td=""><td>-</td></loq<></td></loq<></td></loq<></td></loq<>	<loq< td=""><td><loq< td=""><td><loq< td=""><td>-</td></loq<></td></loq<></td></loq<>	<loq< td=""><td><loq< td=""><td>-</td></loq<></td></loq<>	<loq< td=""><td>-</td></loq<>	-
CBN	ND	ND	ND	ND	-
Total THC	ND	ND	ND	ND	-
Total CBD	40.26	4.026	33.73	1012.02	-
Total Cannabinoids	40.26	4.026	33.73	1012.02	-
Sum of Cannabinoids	42.30	4.230	35.45	1063.49	-
Serving Weight (g)	0.8380				
Package Weight (g)	25.14				

#### Comments

Reported results and measurements are based off of a calculated hypothetical weight using the ratio between filling weight and total capsule weight as per client instruction. Only the filling material was tested.

This result of this sample is confirmed with a retest.

Reported by **Anresco, Inc.** 



September 21, 2024

ND = None Detected LOD = Limit of Detection (0.1333 mg/g) LOQ = Limit of Quantitation (0.4000 mg/g) Total THC =  $\Delta 8$ -THC +  $\Delta 9$ -THC + (0.877 \* THCA) Total CBD = CBD + (0.877 \* CBDA) Total Cannabinoids =  $\Sigma$  (neutral cannabinoids) + [ $0.877 * \Sigma$  (acidic cannabinoids)]

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave., San Francisco, CA 94124 Sample #: 1244239 Batch #: A107220824 page **1** of **1** Report ID: T-5



#### September 19, 2024

#### **CV SCIENCES, INC.** 9530 Padgett Street, Suite 107 San Diego, CA 92126

Order No. 560989 Sample No. 1244239

**Certificate of Analysis** 

#### SAMPLE INFORMATION

Description	FP-24-0086 PlusCBD Relief Softgels 60ct SKU 608 exp 07/26
Lot Number	A107220824
Category (Type)	Non-Inhalable Edible (Capsule)
Received	September 17, 2024

#### ANALYTICAL RESULTS

Analysis	Pesticide Screen 🔮 Pass
Instrument	Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)
Method	MF-CHEM-13
Analysis Date	September 17, 2024 to September 19, 2024

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Abamectin	0.04/0.10	ND	0.3	Pass
Acephate	0.02/0.06	ND	5.0	Pass
Acequinocyl	0.04/0.10	ND	4.0	Pass
Acetamiprid	0.017/0.05	ND	5.0	Pass
Aldicarb	0.02/0.06	ND	0.02	Pass
Azoxystrobin	0.02/0.06	ND	40.0	Pass
Bifenazate	0.02/0.06	ND	5.0	Pass
Bifenthrin	0.04/0.10	ND	0.5	Pass
Boscalid	0.02/0.06	ND	10.0	Pass
Captan	0.2/0.6	ND	5.0	Pass
Carbaryl	0.02/0.06	ND	0.5	Pass
Carbofuran	0.017/0.05	ND	0.017	Pass
Chlorantraniliprole	0.02/0.06	ND	40.0	Pass
Chlordane	0.02/0.06	ND	0.02	Pass
Chlorfenapyr	0.02/0.06	ND	0.02	Pass
Chlorpyrifos	0.02/0.06	ND	0.02	Pass
Clofentezine	0.02/0.06	ND	0.5	Pass
Coumaphos	0.02/0.06	ND	0.02	Pass
Cyfluthrin	0.10/0.30	ND	1.0	Pass
Cypermethrin	0.10/0.30	ND	1.0	Pass
Daminozide	0.017/0.05	ND	0.017	Pass
DDVP (Dichlorvos)	0.013/0.04	ND	0.013	Pass
Diazinon	0.017/0.05	ND	0.2	Pass
Dimethoate	0.017/0.05	ND	0.017	Pass
Dimethomorph	0.017/0.05	ND	20.0	Pass
Ethoprop(hos)	0.02/0.06	ND	0.02	Pass
Etofenprox	0.02/0.06	ND	0.02	Pass
Etoxazole	0.02/0.06	ND	1.5	Pass
Fenhexamid	0.017/0.05	ND	10.0	Pass
Fenoxycarb	0.02/0.06	ND	0.02	Pass
Fenpyroximate	0.02/0.06	ND	2.0	Pass

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratorieswww.anresco.comSample #: 1244239page 1 of 21375 Van Dyke Ave., San Francisco, CA 94124Batch #: A107220824Report ID: T-2



## **Certificate of Analysis**

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Fipronil	0.02/0.06	ND	0.02	Pass
Flonicamid	0.02/0.06	ND	2.0	Pass
Fludioxonil	0.02/0.06	ND	30.0	Pass
Hexythiazox	0.02/0.06	ND	2.0	Pass
Imazalil	0.02/0.06	ND	0.02	Pass
Imidacloprid	0.02/0.06	ND	3.0	Pass
Kresoxim Methyl	0.02/0.06	ND	1.0	Pass
Malathion	0.017/0.05	ND	5.0	Pass
Metalaxyl	0.017/0.05	ND	15.0	Pass
Methiocarb	0.02/0.06	ND	0.02	Pass
Methomyl	0.013/0.04	ND	0.1	Pass
Methyl parathion	0.02/0.06	ND	0.02	Pass
Mevinphos	0.02/0.06	ND	0.02	Pass
Myclobutanil	0.02/0.06	ND	9.0	Pass
Naled	0.017/0.05	ND	0.5	Pass
Oxamyl	0.013/0.04	ND	0.2	Pass
Paclobutrazol	0.02/0.06	ND	0.02	Pass
Pentachloronitrobenzene	0.017/0.05	ND	0.2	Pass
Permethrins	0.10/0.30	ND	20.0	Pass
Phosmet	0.02/0.06	ND	0.2	Pass
Piperonyl Butoxide	0.017/0.05	ND	8.0	Pass
Prallethrin	0.04/0.10	ND	0.4	Pass
Propiconazole	0.02/0.06	ND	20.0	Pass
Propoxur	0.013/0.04	ND	0.013	Pass
Pyrethrins	0.15/0.50	ND	1.0	Pass
Pyridaben	0.017/0.05	ND	3.0	Pass
Spinetoram	0.02/0.06	ND	3.0	Pass
Spinosad	0.02/0.06	ND	3.0	Pass
Spiromesifen	0.04/0.10	ND	12.0	Pass
Spirotetramat	0.02/0.06	ND	13.0	Pass
Spiroxamine	0.017/0.05	ND	0.017	Pass
Tebuconazole	0.02/0.06	ND	2.0	Pass
Thiacloprid	0.013/0.04	ND	0.013	Pass
Thiamethoxam	0.02/0.06	ND	4.5	Pass
Trifloxystrobin	0.02/0.06	ND	30.0	Pass

Reported by **Anresco, Inc.** 



September 19, 2024

ND = None Detected LOD = Limit of Detection LOQ = Limit of Quantitation

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave., San Francisco, CA 94124 Sample #: 1244239 Batch #: A107220824 page**2** of **2** Report ID: T-2



#### September 19, 2024

#### **CV SCIENCES, INC.** 9530 Padgett Street, Suite 107 San Diego, CA 92126

Order No. 560989 Sample No. 1244239

**Certificate of Analysis** 

#### SAMPLE INFORMATION

Description	FP-24-0086 PlusCBD Relief Softgels 60ct SKU 608 exp 07/26
Lot Number	A107220824
Category (Type)	Non-Inhalable Edible (Capsule)
Received	September 17, 2024

#### **ANALYTICAL RESULTS**

Analysis	Residual Solvent Screen 🔮 Pass		
Instrument	Gas Chromatography Mass Spectrometry (GC/MS)		
Method	MF-CHEM-32		
Analysis Date	September 17, 2024 to September 19, 2024		

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
1,2-Dichloroethane	0.5/0.5	ND	1	Pass
Acetone	57/200	ND	5000	Pass
Acetonitrile	56/200	ND	410	Pass
Benzene	0.5/0.5	ND	1	Pass
n-Butane	45/200	ND	5000	Pass
Chloroform	0.5/0.5	ND	1	Pass
Ethanol	37/200	ND	5000	Pass
Ethyl acetate	38/200	ND	5000	Pass
Ethyl ether	37/200	ND	5000	Pass
Ethylene oxide	0.1/0.5	ND	1	Pass
n-Heptane	135/200	ND	5000	Pass
n-Hexane	49/200	ND	290	Pass
Isopropyl alcohol	57/200	ND	5000	Pass
Methanol	37/200	ND	3000	Pass
Methylene chloride	0.1/0.5	ND	1	Pass
n-Pentane	37/200	ND	5000	Pass
Propane	72/200	ND	5000	Pass
Toluene	49/200	ND	890	Pass
Total xylenes (ortho-, meta-, para-)	58/200	ND	2170	Pass
Trichloroethylene	0.5/0.5	ND	1	Pass

Reported by Anresco, Inc.



September 19, 2024

ND = None Detected LOD = Limit of Detection LOQ = Limit of Quantitation

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave., San Francisco, CA 94124 Sample #: 1244239 Batch #: A107220824 page **1** of **1** Report ID: T-2



#### September 19, 2024

#### **CV SCIENCES, INC.** 9530 Padgett Street, Suite 107 San Diego, CA 92126

Order No. 560989 Sample No. 1244239

**Certificate of Analysis** 

#### SAMPLE INFORMATION

Description Lot Number Category (Type) Received	FP-24-0086 PlusCBD Relief Softgels 60ct SKU 608 exp 07/26 A107220824 Non-Inhalable Edible (Capsule) September 17, 2024	
Received	ANALYTICAL RESULTS	
Analysis	Mycotoxins Screen 🔮 Pass	

Analysis	Mycotoxins Screen V Pass
Instrument	Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)
Method	MF-CHEM-13
Analysis Date	September 17, 2024 to September 19, 2024

Analyte	LOD/LOQ (ppb)	Findings (ppb)	Limit (ppb)	Status
Aflatoxin B1	2/5	ND	-	-
Aflatoxin B2	2/5	ND	-	-
Aflatoxin G1	2/5	ND	-	-
Aflatoxin G2	2/5	ND	-	-
Total Aflatoxins	8/20	ND	20	Pass
Ochratoxin A	6/18	ND	20	Pass

Reported by **Anresco**, Inc.

ND = None Detected LOD = Limit of Detection LOQ = Limit of Quantitation



September 19, 2024

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave., San Francisco, CA 94124



## **Certificate of Analysis**

September 23, 2024

**CV SCIENCES, INC.** 9530 Padgett Street, Suite 107 San Diego, CA 92126 Order No. 560989 Sample No. 1244239

#### SAMPLE INFORMATION

DescriptionFP-24-0086 PlusCBD Relief Softgels 60ct SKU 608 exp 07/26Lot NumberA107220824ReceivedSeptember 17, 2024

#### ANALYTICAL RESULTS

Analysis Date September 17, 2024 to September 23, 2024

Findings	Analysis	Results	Method
	Standard Plate Count	<10 cfu/g	FDA BAM
	Yeast	<10 cfu/g	FDA BAM
	Mold	<10 cfu/g	FDA BAM
	Coliforms	<10 cfu/g	FDA BAM - ECC AGAR
	Escherichia coli	<10 cfu/g	FDA BAM - ECC AGAR
	Salmonella	Negative /10g	MF-MICRO-11 (AOAC 2016.01)
	Staph aureus	Negative /10g	USP <62>

### Reported by **Anresco, Inc.**



If there are any questions with this report, please contact "compliance@anresco.com".

Tel: 415 822 1100 Fax: 415 822 6615 Report ID: S-1

page 1 of 1

This document is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential or protected from disclosure under applicable law. If you have received this document in error, please immediately notify us and return it to the address listed above.



## **Certificate of Analysis**

September 19, 2024

#### CV SCIENCES, INC.

9530 Padgett Street, Suite 107 San Diego, CA 92126 Order No. 560989 Sample No. 1244239

#### SAMPLE INFORMATION

Description	FP-24-0086 PlusCBD Relief Softgels 60ct SKU 608 exp 07/26
Lot Number	A107220824
Category (Type)	Non-Inhalable Edible (Capsule)
Received	September 17, 2024

#### **ANALYTICAL RESULTS**

Analysis	Heavy Metals 🔮 Pass
Instrument	Inductively Coupled Plasma Mass Spectrometry (ICP-MS)
Method	MF-CHEM-16
Analysis Date	September 17, 2024 to September 19, 2024

Analyte	LOD/LOQ (µg/g)	Findings (µg/g)	Limit (µg/g)	Status
Arsenic	0.02/0.05	ND	1.5	Pass
Cadmium	0.02/0.05	ND	0.5	Pass
Mercury	0.02/0.05	ND	3	Pass
Lead	0.02/0.125	ND	0.5	Pass

Reported by **Anresco, Inc.** 



Eric Tam Senior Chemist September 19, 2024 ND = None Detected LOD = Limit of Detection LOQ = Limit of Quantitation

If there are any questions with this report, please contact "compliance@anresco.com".

Anresco Laboratories www.anresco.com 1375 Van Dyke Ave., San Francisco, CA 94124 page **1** of **1** Report ID: T-2

### DocuSign

#### Certificate Of Completion

Envelope Id: CC26837E74404B61934D6A924C413AD1 Subject: FP-24-0086 PlusCBD Relief Softgels 60ct SKU 608 exp 07/26 A107220824 Source Envelope: Document Pages: 9 Signatures: 1 Certificate Pages: 1 Initials: 0 AutoNav: Enabled EnvelopeId Stamping: Enabled Time Zone: (UTC-08:00) Pacific Time (US & Canada)

#### **Record Tracking**

Status: Original 10/1/2024 8:44:29 AM Holder: Vandana Kothari vandana.kothari@cvsciences.com

#### Signer Events

Vandana Kothari vandana.kothari@cvsciences.com DIRECTOR OF QUALITY CV Sciences - Part 11 Security Level: Email, Account Authentication (Required)

Vandana kothari

Signature

Signature Adoption: Pre-selected Style Signature ID: 87A410FF-F032-4873-8900-BEED0868E359 Using IP Address: 75.85.176.253

With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document

Status: Completed

Envelope Originator: Vandana Kothari vandana.kothari@cvsciences.com IP Address: 64.207.219.136

Location: DocuSign

### Timestamp

Sent: 10/1/2024 8:45:08 AM Viewed: 10/1/2024 8:47:36 AM Signed: 10/1/2024 8:48:52 AM

Electronic Record and Signature Disclosure:
Not Offered via DocuSign

In Person Signer Events	Signature	Timestamp
Editor Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp
Certified Delivery Events	Status	Timestamp
Carbon Copy Events	Status	Timestamp
Witness Events	Signature	Timestamp
Notary Events	Signature	Timestamp
Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	10/1/2024 8:45:08 AM
Certified Delivered	Security Checked	10/1/2024 8:47:36 AM
Signing Complete	Security Checked	10/1/2024 8:48:52 AM
Completed	Security Checked	10/1/2024 8:48:52 AM
Payment Events	Status	Timestamps